Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis
August 1st, 2019
8.2K views
This protocol describes the establishment of a tumor-bearing mouse model to monitor tumor progression and angiogenesis in real-time by dual bioluminescence imaging.
Overview
This protocol describes the establishment of a tumor-bearing mouse model to monitor tumor progression and angiogenesis in real-time by dual bioluminescence imaging. The model allows for simultaneous tracking of tumor growth and angiogenesis using Firefly and Renilla luciferase imaging.
Key Study Components
Area of Science
- Oncology
- Imaging Techniques
- Animal Models
Background
- Angiogenesis plays a crucial role in tumor metastasis and progression.
- Monitoring tumor dynamics is essential for understanding cancer biology.
- Dual bioluminescence imaging provides a powerful tool for real-time observation.
- This model can be applied in antitumor drug screening and oncology research.
Purpose of Study
- To establish a reliable mouse model for studying tumor progression.
- To monitor angiogenesis in real-time.
- To evaluate therapeutic strategies in oncology.
Methods Used
- Establishment of a tumor-bearing mouse model.
- Use of dual bioluminescence imaging with Firefly and Renilla luciferase.
- Real-time tracking of tumor growth and angiogenesis.
- Application in drug screening and molecular process detection.
Main Results
- Successful monitoring of tumor progression and regression.
- Real-time detection of tumor-related molecular processes.
- Demonstration of the model's applicability in therapeutic evaluations.
- Insights into the role of angiogenesis in tumor dynamics.
Conclusions
- The dual bioluminescence imaging model is effective for studying tumors.
- This approach enhances the understanding of tumor biology.
- It holds potential for future oncology research and drug development.
Frequently Asked Questions
What is dual bioluminescence imaging?
Dual bioluminescence imaging is a technique that allows for the simultaneous visualization of two different biological processes using two types of luciferase enzymes.
How does this model help in cancer research?
This model enables researchers to monitor tumor growth and angiogenesis in real-time, providing insights into tumor behavior and treatment responses.
What types of cancers can this model be applied to?
While this protocol specifically mentions breast cancer, the model can potentially be adapted for other types of tumors.
What are the advantages of using a mouse model?
Mouse models closely mimic human disease, allowing for more relevant preclinical studies and better understanding of tumor biology.
Can this method be used for drug screening?
Yes, the dual bioluminescence imaging model can be used to evaluate the efficacy of antitumor drugs in real-time.
What is the significance of monitoring angiogenesis?
Monitoring angiogenesis is crucial as it is a key process in tumor progression and metastasis, influencing treatment outcomes.
Executive Industry Relevance
This dual bioluminescence imaging model enables real-time, simultaneous monitoring of tumor progression and angiogenesis in vivo, addressing a critical gap in preclinical oncology research. By providing quantitative, longitudinal readouts of both tumor burden and vascular dynamics in a single animal, the approach supports mechanistic de-risking of anti-tumor therapeutics and improves predictive confidence in target validation. The model is directly applicable to antitumor drug screening and oncology research, offering a scalable platform for evaluating therapeutic efficacy and angiogenesis modulation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by correlating tumor growth with angiogenesis dynamics in real-time.
- Operational Value: Provides a disease-relevant system for functional target validation of angiogenesis-related pathways.
- Predictive Value: Supports predictive confidence through longitudinal, quantitative bioluminescence readouts that reflect tumor-angiogenesis coupling.
Screening & Assay Development
- Assay Readiness: Generates standardized, reproducible bioluminescence signals from luciferase-labeled cells for consistent compound evaluation.
- Quantitative Output: Delivers sensitive, linear measurements of tumor progression (Renilla) and angiogenesis (Firefly) enabling dose-response analysis.
- Screening Scalability: Supports high-content, longitudinal screening in live animals with minimal animal use through repeated imaging sessions.
Translational & Preclinical Research
- Translational Continuity: Models human tumor angiogenesis and growth dynamics, facilitating preclinical validation of anti-tumor and anti-angiogenic strategies.
- Mechanistic De-risking: Allows detection of tumor-related molecular processes in response to therapeutic interventions, reducing biological ambiguity.
- Risk-Adjusted Advancement: Enables go/no-go decisions based on dual-modality efficacy signals, improving portfolio prioritization.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, supporting iterative evaluation of tumor-angiogenesis relationships.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling simultaneous visualization of tumor cells and angiogenic activity.
- Screening: Delivers assay-ready, reproducible bioluminescence outputs that allow reliable comparison of compound effects on tumor and vascular compartments.
- Analytics: Provides quantitative, normalized light output measurements that facilitate statistical comparison across treatment groups and time points.
- Translational Research: Connects discovery findings to preclinical continuity by modeling angiogenesis-dependent tumor progression in immunocompetent hosts.
- Enterprise Reuse: Establishes a reusable imaging platform applicable across oncology programs for longitudinal target and phenotype monitoring.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by providing direct, correlative evidence between tumor growth and angiogenesis in vivo.
- Operational Value: Ensures standardization and reproducibility through dual-luciferase normalization and internal signal controls.
- Strategic Value: Improves capital efficiency by enabling early detection of ineffective therapeutics through dual-modality response profiling.
- Portfolio Impact: Enhances risk-adjusted prioritization by identifying compounds that dissociate tumor growth from angiogenesis or concurrently modulate both.
Implementation Considerations
- Requires expertise in lentiviral transduction, luciferase-based imaging, and in vivo tumor model handling.
- Dependent on access to a living imaging system capable of sequential Renilla and Firefly luciferase detection with appropriate substrate injection.
- Necessitates cross-team standardization of imaging protocols, substrate dosing, and anesthesia procedures for longitudinal consistency.
- Involves adaptation considerations when extending the model to other tumor types or stromal compartments beyond subcutaneous mammary fat pad.
- Practical limitations include the need for biosafety level II facilities due to lentivirus handling and potential signal attenuation in deep tissues over time.
Biopharma FAQs
Why does dual luciferase imaging matter for target validation?
Dual luciferase imaging enables simultaneous, real-time tracking of tumor progression and angiogenesis, providing correlative data that supports mechanistic validation of targets involved in tumor-angiogenesis crosstalk. This approach reduces biological ambiguity by linking phenotypic outcomes to vascular dynamics in vivo.
How does isolating tumor and angiogenesis signals support the discovery pipeline?
By using Renilla luciferase to label tumor cells and Firefly luciferase under an angiogenesis-inducible promoter, the model isolates independent variables—tumor burden and vascular response—allowing deconvolution of their contributions to phenotype. This enables precise hypothesis testing in early discovery.
What quantitative measurements does dual bioluminescence enable?
The method provides normalized photon flux measurements from Renilla and Firefly luciferase signals, allowing quantitative comparison of tumor growth (RLuc) and angiogenesis (FLuc) over time and across treatment groups. These outputs support dose-response and kinetic analysis.
Why are replication requirements important for cross-functional collaboration?
Reproducible bioluminescence signals across animals and experiments ensure that tumor and angiogenesis readouts are reliable, enabling consistent data interpretation between discovery, preclinical, and translational teams. Standardized imaging protocols are essential for multi-site validation.
What statistical capabilities are needed before implementing this model?
Implementation requires the ability to perform longitudinal statistical analysis, including repeated measures ANOVA or mixed-effects modeling, to compare dual-luciferase signals across time points and treatment conditions while accounting for inter-animal variability.
Chapters in this video
0:04
Title
1:33
Lentivirus-Renilla-Luciferin-Red Fluorescent Protein (LV-Rluc-RFP; RR) and LV-Rluc-RFP-Herpes Simplex Virus Truncated Thymidine Kinase (HSV-ttk) (LV-Rluc-RFP-TTK; RT) Packaging and Production
3:38
LV-RR and LV-RRT Lentiviral Transduction for Gene Expression in 4T1 Cells
4:37
Drug Screening and LV-RR and LV-RRT-Transduced 4T1 Cell Identification
5:18
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-Firefly Luciferase (Fluc)-Knockin (KI) Mice and Tumor-Bearing Mouse Model
6:50
Dual Bioluminescence Tumor (Rluc) and Angiogenesis (Fluc) Imaging
7:58
Results: Representative In Situ Tumor Growth and Angiogenesis Visualization and Analysis
9:52
Conclusion
